Celldex Therapeutics (NASDAQ:CLDX) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapy treatments for cancer and neurological diseases. Founded in 2000 and headquartered in Hampton, New Jersey, the company leverages its proprietary antibody and vaccine platforms to modulate the immune system and address a range of medical conditions with significant unmet needs. Celldex’s research efforts center on engineering monoclonal antibodies and peptide-based vaccines that harness immune cells to recognize and eliminate disease-causing targets.
At the core of Celldex’s pipeline are multiple investigational therapies designed to engage the body’s innate and adaptive immunity. Lead programs include CDX-914, a RIG-I agonist intended to stimulate antiviral and antitumor responses, and CDX-574, a next-generation antibody targeting a checkpoint pathway implicated in tumor immune evasion. These candidates have advanced into early- to mid-stage clinical trials, where they are being evaluated both as monotherapies and in combination with established treatments such as checkpoint inhibitors and anti–PD-1 antibodies.
Celldex conducts its clinical development activities across the United States, Europe and Canada, collaborating with academic medical centers, contract research organizations and pharmaceutical partners to execute its trial programs. The company’s global footprint enables it to enroll diverse patient populations and generate robust data on safety and efficacy. Strategic alliances have supplemented Celldex’s internal capabilities, granting access to complementary technologies and expediting the translation of laboratory discoveries into potential therapeutic options.
Under the leadership of President and Chief Executive Officer Wayne B. Golde, M.D., Celldex maintains a commitment to scientific rigor and patient-centric innovation. The management team brings together expertise in immunology, oncology and clinical development, with previous experience at both biotech start-ups and large pharmaceutical companies. As a publicly traded entity listed on the NASDAQ under the ticker CLDX, Celldex Therapeutics continues to advance its portfolio with the aim of delivering novel, life-changing therapies to patients worldwide.
